Compare iShares Self-Driving EV and Tech (IDRV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Viatris Inc — how do they compare? iShares Self-Driving EV and Tech trades at $35.9, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while iShares Self-Driving EV and Tech pays none, and Viatris Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $17.39 |
52-Week Low | $32.13 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.
The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
